FindMyRecallSubscribe
Class II: temporary or reversible health riskOngoing

Ascend Laboratories Rizatriptan Benzoate Tablets Recall

Rizatriptan Benzoate Tablets, USP, 5 mg, 18 (3x6) Unit Dose Tablets, Rx Only, Manufactu…

Ascend Laboratories, LLC · Bedminster, NJ

Risk level
Class II
Reported by FDA
Jul 23, 2025
Recall ID
D-0533-2025
Check your lot numberHow we source this data

Summary

Ascend Laboratories recalled Rizatriptan Benzoate Tablets starting Jul 9, 2025. The FDA classified it as Class II (temporary or reversible health risk) and published enforcement report D-0533-2025 on Jul 23, 2025. Reason: CGMP Deviations: detection of N-nitroso-dimethyl-rizatriptan impurity, above the FDA recommended acceptable intake limit. Status: Ongoing.

Why it was recalled

CGMP Deviations: detection of N-nitroso-dimethyl-rizatriptan impurity, above the FDA recommended acceptable intake limit.

Product description

Rizatriptan Benzoate Tablets, USP, 5 mg, 18 (3x6) Unit Dose Tablets, Rx Only, Manufactured by: Alkem Laboratories Ltd., INDIA, Distributed by: Ascend Laboratories LLC, Parsippany, NJ 07054, NDC 67877-261-18

Lot numbers, UPCs & expiration codes

Lot 23142117, 23142119, 23142122, Exp Date: May 2026; Lot 24142625, Exp Date: Jun. 2027

Where it was sold

US Nationwide.

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0533-2025
Classification
Class II
Status
Ongoing
Recall initiated
Jul 9, 2025
FDA report date
Jul 23, 2025
Quantity
N/A
Recall type
Voluntary: Firm initiated
Recalling firm
Ascend Laboratories, LLC

Original FDA data

Every field from FDA enforcement report D-0533-2025, exactly as published.

Show all FDA fields
City
Bedminster
State
NJ
Status
Ongoing
Country
United States
Event ID
96770
Address
135 Us Highway 202 206 Ste 15
Code information
Lot 23142117, 23142119, 23142122, Exp Date: May 2026; Lot 24142625, Exp Date: Jun. 2027
Postal code
07921-2608
Report date
Jul 23, 2025
Product type
Drugs
Recall number
D-0533-2025
Classification
Class II
Recalling firm
Ascend Laboratories, LLC
Reason for recall
CGMP Deviations: detection of N-nitroso-dimethyl-rizatriptan impurity, above the FDA recommended acceptable intake limit.
Voluntary / mandated
Voluntary: Firm initiated
Product description
Rizatriptan Benzoate Tablets, USP, 5 mg, 18 (3x6) Unit Dose Tablets, Rx Only, Manufactured by: Alkem Laboratories Ltd., INDIA, Distributed by: Ascend Laboratories LLC, Parsippany, NJ 07054, NDC 67877-261-18
Distribution pattern
US Nationwide.
Recall initiation date
Jul 9, 2025
Initial firm notification
Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit
Center classification date
Jul 17, 2025

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0533-2025, published Jul 23, 2025. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls